Puma (PBYI) Q1 Loss Narrows, Focus Remains On Neratinib
May 11, 2017 at 11:10 AM EDT
Puma Biotechnology, Inc. reported a first-quarter 2017 loss of $1.97 per share narrower than the Zacks Consensus Estimate of a loss of $2.08 and the year-ago loss of $2.19.
